Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors

[1]  R. Capasso,et al.  Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon , 2007, Journal of Molecular Medicine.

[2]  M. Storr.  TRPV1 in colitis: is it a good or a bad receptor? – a viewpoint , 2007, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[3]  R. Duerr.  Genome-wide association studies herald a new era of rapid discoveries in inflammatory bowel disease research. , 2007, Gastroenterology.

[4]  Judy H Cho,et al.  Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis , 2007, Nature Genetics.

[5]  Simon Heath,et al.  Novel Crohn Disease Locus Identified by Genome-Wide Association Maps to a Gene Desert on 5p13.1 and Modulates Expression of PTGER4 , 2007, PLoS genetics.

[6]  Stefan Wirtz,et al.  Chemically induced mouse models of intestinal inflammation , 2007, Nature Protocols.

[7]  S. Schoenberg,et al.  Predictive value of the CARD15 variant 1007fs for the diagnosis of intestinal stenoses and the need for surgery in Crohn's disease in clinical practice: Results of a Prospective Study , 2006, Inflammatory bowel diseases.

[8]  A. Ciccodicola,et al.  Experimental colitis: decreased Octn2 and Atb0+ expression in rat colonocytes induces carnitine depletion that is reversible by carnitine‐loaded liposomes , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  C. Schneider,et al.  Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[10]  R. Sartor.  Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis , 2006, Nature Clinical Practice Gastroenterology &Hepatology.

[11]  M. Valenti,et al.  Up‐regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  H. Lehr,et al.  CB1 and TRPV1 receptors mediate protective effects on colonic electrophysiological properties in mice , 2006, Journal of Molecular Medicine.

[13]  S. Brand,et al.  Eight novel CARD15 variants detected by DNA sequence analysis of the CARD15 gene in 111 patients with inflammatory bowel disease , 2006, Immunogenetics.

[14]  M. Storr,et al.  Perspektiven von Cannabinoiden in der Gastroenterologie , 2006 .

[15]  G. Marsicano,et al.  Vanilloid receptor (TRPV1)-deficient mice show increased susceptibility to dinitrobenzene sulfonic acid induced colitis , 2006, Journal of Molecular Medicine.

[16]  R. Puffenbarger.  Molecular biology of the enzymes that degrade endocannabinoids. , 2005, Current drug targets. CNS and neurological disorders.

[17]  J. Davison,et al.  Review article: endocannabinoids and their receptors in the enteric nervous system , 2005, Alimentary pharmacology & therapeutics.

[18]  C. Fowler,et al.  Inhibitors of fatty acid amide hydrolase reduce carrageenan‐induced hind paw inflammation in pentobarbital‐treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors , 2005, British journal of pharmacology.

[19]  R. Capasso,et al.  Fatty acid amide hydrolase controls mouse intestinal motility in vivo. , 2005, Gastroenterology.

[20]  B. Lutz,et al.  The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract , 2005, Journal of Molecular Medicine.

[21]  A. Gerber,et al.  Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH) , 2005, International Journal of Obesity.

[22]  R. Razdan,et al.  Further advances in the synthesis of endocannabinoid-related ligands , 2005, The AAPS Journal.

[23]  S. Gaetani,et al.  Characterization of the Fatty Acid Amide Hydrolase Inhibitor Cyclohexyl Carbamic Acid 3′-Carbamoyl-biphenyl-3-yl Ester (URB597): Effects on Anandamide and Oleoylethanolamide Deactivation , 2005, Journal of Pharmacology and Experimental Therapeutics.

[24]  P. Holzer.  Vanilloid receptor TRPV1: hot on the tongue and inflaming the colon , 2004, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[25]  B. Cravatt,et al.  Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. , 2004, Human molecular genetics.

[26]  B. Cravatt,et al.  The endogenous cannabinoid system protects against colonic inflammation. , 2004, The Journal of clinical investigation.

[27]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[28]  H. Schmid,et al.  Endocannabinoids Induce Ileitis in Rats via the Capsaicin Receptor (VR1) , 2003, Journal of Pharmacology and Experimental Therapeutics.

[29]  M. Zeitz,et al.  Animal Models of Inflammatory Bowel Disease: An Overview , 2003, Pathobiology.

[30]  B. Cravatt,et al.  The enzymatic inactivation of the fatty acid amide class of signaling lipids. , 2002, Chemistry and physics of lipids.

[31]  W. Zieglgänsberger,et al.  The endogenous cannabinoid system controls extinction of aversive memories , 2002, Nature.

[32]  B. Cravatt,et al.  A missense mutation in human fatty acid amide hydrolase associated with problem drug use , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Herkenham,et al.  International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors , 2002, Pharmacological Reviews.

[34]  R. Capasso,et al.  Cannabinoid CB1‐receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation , 2001, British journal of pharmacology.

[35]  K. Mackie,et al.  Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. , 2001, Gastroenterology.

[36]  R. Pertwee.  Cannabinoids and the gastrointestinal tract , 2001, Gut.

[37]  T. Bonner,et al.  Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. , 2000, European journal of pharmacology.

[38]  J. Bakalar,et al.  Marihuana as medicine. A plea for reconsideration. , 1995, JAMA.

[39]  J. Wallace,et al.  An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. , 1990, The American journal of physiology.

[40]  Michael Camilleri,et al.  Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[41]  K. Mackie,et al.  Identification functional characterization of brainstem cannabinoid CB2 receptors. , 2022 .